跳至主要内容
临床试验/NCT01104402
NCT01104402已完成不适用

Early Intervention in Cystic Fibrosis Exacerbation

Johns Hopkins University6 个研究点 分布在 1 个国家目标入组 267 人开始时间: 2011年10月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
267
试验地点
6
主要终点
Change in FEV1

研究概览

简要总结

Individuals with cystic fibrosis (CF) develop chronic lung infections and suffer intermittent acute exacerbations of their lung disease. Most exacerbations are not treated until they cause increased symptoms, and patients seek medical attention. This proposal details a study of home lung function and symptom monitoring. Subjects will be randomly assigned to one of two groups: 1) home monitoring, in which spirometry and symptoms are recorded; or 2) standard care. The home monitoring data will be transmitted electronically to the study center. If spirometry or symptoms have deteriorated substantially, treatment for a CF pulmonary exacerbation will be initiated. It is anticipated that use of home monitoring will lead to earlier, more reliable recognition and treatment of exacerbations, which will translate into better lung health.

详细描述

Individuals with CF develop chronic lung infections and suffer intermittent exacerbations, which require intensive treatment with antibiotics. The most common and useful objective measure of CF lung disease is spirometry. Chronic treatment of CF lung disease requires airway clearance, mucolytics and antibiotics. These treatments have been quite successful and there is evidence that early, aggressive treatment of lung disease results in better outcomes. Unfortunately, most exacerbations are not treated until they cause pronounced deterioration in symptoms, which prompts patients to seek medical attention. Self-monitoring of clinical status has improved outcomes in many other disorders such as asthma, diabetes mellitus, and lung transplantation. This is an important, randomized trial of home lung function and symptom monitoring in CF. Subjects will be assigned to one of two groups: 1) Home monitoring, in which spirometry and symptoms are recorded daily; or 2) Standard Care. The home monitoring data will be transmitted electronically twice weekly to the study center, where the results will be reviewed. If spirometry or symptoms have deteriorated substantially below baseline, treatment for a CF pulmonary exacerbation will be initiated. It is anticipated that use of home monitoring will translate into better clinical outcomes. We will test the hypothesis that if pulmonary exacerbations are identified and treated earlier than the current standard of care, the progression of lung disease will be slowed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CF diagnosis confirmed with sweat test, abnormal nasal potential difference and/or genetic testing
  • Age 14 and older
  • Able to perform spirometry
  • Clinically stable without antibiotic treatment for a pulmonary exacerbation in the two weeks prior to the screening visit
  • Forced expiratory volume in the first second (FEV1) greater than 25% of predicted at screening

排除标准

  • History of solid organ transplant
  • Participation in any interventional trial within the last 30 days
  • Inability to speak and read the English language well enough to complete questionnaires
  • Colonization with Burkholderia cepacia genomovar III within the last 24 months
  • Currently receiving antimicrobial treatment specifically used to treat active non-tuberculosis mycobacterium
  • Confirmed diagnosis of allergic bronchopulmonary aspergillosis (ABPA) as defined by the Cystic Fibrosis Foundation (CFF) guidance document that is being actively treated

研究组 & 干预措施

Standard Care

No Intervention

Subjects will receive education about signs and symptoms indicative of worsening CF.

Home monitoring

Active Comparator

Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.

干预措施: Home lung function and symptom monitoring (Device)

结局指标

主要结局

Change in FEV1

时间窗: 12 months

The primary outcome variable is FEV1 which will be obtained at quarterly study visits. The primary analysis will use a linear mixed effects model incorporating all FEV1 measurements to estimate the 52-week change in FEV1

次要结局

  • Pulmonary Exacerbations(12 months)
  • Treatment Burden(Change from baseline to 12 months)
  • Change in Health Related Quality of Life Scores as Assessed by the Cystic Fibrosis Questionnaire Revised (CFQ-R) (Respiratory Subscale Only((Change from baseline to 12 months)
  • Serious Adverse Events (SAE)(12 months)
  • Cystic Fibrosis Respiratory Symptom Diary (CFRSD)(12 months)
  • Change in Prevalence of Resistant Species of Bacteria(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Early Intervention in Cystic Fibrosis Exacerbation | 临床试验